KR102669985B1 - Btla 융합 단백질 작용제 및 이의 용도 - Google Patents

Btla 융합 단백질 작용제 및 이의 용도 Download PDF

Info

Publication number
KR102669985B1
KR102669985B1 KR1020187002960A KR20187002960A KR102669985B1 KR 102669985 B1 KR102669985 B1 KR 102669985B1 KR 1020187002960 A KR1020187002960 A KR 1020187002960A KR 20187002960 A KR20187002960 A KR 20187002960A KR 102669985 B1 KR102669985 B1 KR 102669985B1
Authority
KR
South Korea
Prior art keywords
hvem
protein
delete delete
btla
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187002960A
Other languages
English (en)
Korean (ko)
Other versions
KR20180016618A (ko
Inventor
칼 에프. 웨어
존 세디
티그란 아이바지안
브라이언 밀러
나타샤 케이. 크렐린
Original Assignee
샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트, 화이자 인코포레이티드 filed Critical 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트
Priority to KR1020247017225A priority Critical patent/KR20240110000A/ko
Publication of KR20180016618A publication Critical patent/KR20180016618A/ko
Application granted granted Critical
Publication of KR102669985B1 publication Critical patent/KR102669985B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
KR1020187002960A 2015-06-30 2016-06-29 Btla 융합 단백질 작용제 및 이의 용도 Active KR102669985B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247017225A KR20240110000A (ko) 2015-06-30 2016-06-29 Btla 융합 단백질 작용제 및 이의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187105P 2015-06-30 2015-06-30
US62/187,105 2015-06-30
PCT/US2016/040108 WO2017004213A1 (en) 2015-06-30 2016-06-29 Btla fusion protein agonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247017225A Division KR20240110000A (ko) 2015-06-30 2016-06-29 Btla 융합 단백질 작용제 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20180016618A KR20180016618A (ko) 2018-02-14
KR102669985B1 true KR102669985B1 (ko) 2024-05-29

Family

ID=57609132

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187002960A Active KR102669985B1 (ko) 2015-06-30 2016-06-29 Btla 융합 단백질 작용제 및 이의 용도
KR1020247017225A Pending KR20240110000A (ko) 2015-06-30 2016-06-29 Btla 융합 단백질 작용제 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247017225A Pending KR20240110000A (ko) 2015-06-30 2016-06-29 Btla 융합 단백질 작용제 및 이의 용도

Country Status (13)

Country Link
US (3) US10961297B2 (https=)
EP (1) EP3317297A4 (https=)
JP (4) JP7116285B2 (https=)
KR (2) KR102669985B1 (https=)
CN (2) CN114853903A (https=)
AU (3) AU2016286108B2 (https=)
BR (1) BR112017028316A2 (https=)
CA (1) CA2990885A1 (https=)
EA (1) EA201890171A1 (https=)
IL (2) IL297395B2 (https=)
MX (1) MX2018000073A (https=)
SG (1) SG10201913567QA (https=)
WO (1) WO2017004213A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
CA2990885A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063067A2 (en) * 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
WO2013074738A1 (en) * 2011-11-15 2013-05-23 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
US20030235580A1 (en) 2002-06-24 2003-12-25 Fen Zhang Amniotic membrane mediated delivery of bioactive molecules
WO2004039394A1 (en) 2002-10-25 2004-05-13 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CA2586615C (en) * 2004-11-12 2017-06-27 Genentech, Inc. Pro87299 (btla), and variants thereof, for treating immune related disorders
US8188232B1 (en) 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
US8349320B2 (en) * 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
JPWO2007010692A1 (ja) 2005-07-19 2009-01-29 独立行政法人科学技術振興機構 Ｈｖｅｍ及びｂｔｌａを標的とした炎症性腸疾患治療用医薬組成物及び治療方法
KR20090088891A (ko) 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
US9700606B2 (en) 2008-07-08 2017-07-11 La Jolla Institute For Allergy And Immunology HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use
US8318662B2 (en) 2009-03-16 2012-11-27 Korea Institute Of Radiological & Medical Sciences Protein increasing cell infectivity of herpes simplex virus and use thereof
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
CN102762593B (zh) * 2009-07-31 2015-05-20 梅达雷克斯有限责任公司 抗btla的完全人抗体
CA2923314A1 (en) 2013-09-05 2015-03-12 Sanford-Burnham Medical Research Institute Modulation of .gamma..delta.t cells
US11261232B2 (en) 2015-04-02 2022-03-01 Memorial Sloan Kettering Cancer Center TNFRSF14 / HVEM proteins and methods of use thereof
EP3288587A4 (en) 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
CA2990885A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
US20230183346A1 (en) 2016-02-26 2023-06-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
WO2017211321A1 (zh) 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
TWI847958B (zh) 2016-07-05 2024-07-11 英屬開曼群島商北極星藥業集團股份有限公司 用精胺酸耗盡劑進行之組合癌症免疫療法
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
AU2018250641B2 (en) 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
JP2020521759A (ja) 2017-05-26 2020-07-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ
JP7837141B2 (ja) 2017-10-27 2026-03-30 シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法
US20200270355A1 (en) 2017-11-09 2020-08-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
EP3802602A1 (en) 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
CN112533629A (zh) 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
CN112384532B (zh) 2018-06-29 2025-01-10 艾利妥 抗SIRP-β1抗体及其使用方法
JP7713880B2 (ja) 2018-08-20 2025-07-28 ザ ジェネラル ホスピタル コーポレイション アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド
CA3109563A1 (en) 2018-09-14 2020-03-19 Universite De Lausanne Methods for modulating regulatory t cells and inhibiting tumor growth
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063067A2 (en) * 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
WO2013074738A1 (en) * 2011-11-15 2013-05-23 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders

Also Published As

Publication number Publication date
EA201890171A1 (ru) 2018-08-31
JP7116285B2 (ja) 2022-08-10
CN108026159B9 (zh) 2022-07-05
EP3317297A1 (en) 2018-05-09
JP2021113240A (ja) 2021-08-05
AU2016286108A8 (en) 2018-02-22
IL256383B2 (en) 2023-03-01
CN108026159B (zh) 2022-05-27
IL297395B2 (en) 2024-01-01
KR20240110000A (ko) 2024-07-12
SG10201913567QA (en) 2020-02-27
AU2021203768A1 (en) 2021-07-08
WO2017004213A1 (en) 2017-01-05
CN114853903A (zh) 2022-08-05
IL256383A (en) 2018-02-28
CN108026159A (zh) 2018-05-11
IL256383B (en) 2022-11-01
AU2021203768B2 (en) 2023-01-19
BR112017028316A2 (en) 2018-09-04
JP2024019529A (ja) 2024-02-09
US20220025017A1 (en) 2022-01-27
IL297395B1 (en) 2023-09-01
US11939367B2 (en) 2024-03-26
IL297395A (en) 2022-12-01
KR20180016618A (ko) 2018-02-14
CA2990885A1 (en) 2017-01-05
MX2018000073A (es) 2018-06-27
JP7559013B2 (ja) 2024-10-01
JP2022141840A (ja) 2022-09-29
US20180170999A1 (en) 2018-06-21
US10961297B2 (en) 2021-03-30
US20240247047A1 (en) 2024-07-25
AU2023202302A1 (en) 2023-05-11
AU2016286108A1 (en) 2018-02-15
AU2016286108B2 (en) 2021-03-11
JP2018521999A (ja) 2018-08-09
EP3317297A4 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
AU2021203768B2 (en) BTLA fusion protein agonists and uses thereof
US20230019085A1 (en) Psgl-1 modulators and uses thereof
US20220380468A1 (en) Modulation of immune response using btla agonist antibodies
US20220267429A1 (en) Use of tgf-alpha polypeptide or anti-tgf-alpha antibodies for the treatment of diseases and disorders
EA043600B1 (ru) Слитые белки btla агонисты и их применение

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601